DXCM Dexcom Inc

Price (delayed)

$94.14

Market cap

$36.51B

P/E Ratio

101.23

Dividend/share

N/A

EPS

$0.93

Enterprise value

$38.63B

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in ...

Highlights
Dexcom's net income has soared by 55% YoY and by 22% from the previous quarter
The EPS has soared by 55% YoY and by 22% QoQ
The quick ratio has declined by 48% year-on-year but it has grown by 23% since the previous quarter
The debt has soared by 60% YoY and by 59% from the previous quarter
The company's equity fell by 7% YoY and by 6% QoQ

Key stats

What are the main financial stats of DXCM
Market
Shares outstanding
387.87M
Market cap
$36.51B
Enterprise value
$38.63B
Valuations
Price to book (P/B)
17.37
Price to sales (P/S)
11.38
EV/EBIT
79.61
EV/EBITDA
59.79
EV/Sales
12.08
Earnings
Revenue
$3.2B
EBIT
$485.3M
EBITDA
$646.1M
Free cash flow
$466M
Per share
EPS
$0.93
Free cash flow per share
$1.21
Book value per share
$5.42
Revenue per share
$8.27
TBVPS
$17.17
Balance sheet
Total assets
$6.82B
Total liabilities
$4.72B
Debt
$3.31B
Equity
$2.1B
Working capital
$2.93B
Liquidity
Debt to equity
1.58
Current ratio
2.42
Quick ratio
2.12
Net debt/EBITDA
3.28
Margins
EBITDA margin
20.2%
Gross margin
63.9%
Net margin
11.2%
Operating margin
14%
Efficiency
Return on assets
6.3%
Return on equity
17.3%
Return on invested capital
8.9%
Return on capital employed
10.2%
Return on sales
15.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DXCM stock price

How has the Dexcom stock price performed over time
Intraday
0.9%
1 week
9.39%
1 month
-7.61%
1 year
16.89%
YTD
-16.87%
QTD
0.9%

Financial performance

How have Dexcom's revenue and profit performed over time
Revenue
$3.2B
Gross profit
$2.04B
Operating income
$448.2M
Net income
$357.5M
Gross margin
63.9%
Net margin
11.2%
DXCM's operating income has surged by 89% year-on-year and by 13% since the previous quarter
The operating margin has surged by 57% year-on-year and by 7% since the previous quarter
Dexcom's net income has soared by 55% YoY and by 22% from the previous quarter
The net margin has increased by 30% YoY and by 15% from the previous quarter

Growth

What is Dexcom's growth rate over time

Valuation

What is Dexcom stock price valuation
P/E
101.23
P/B
17.37
P/S
11.38
EV/EBIT
79.61
EV/EBITDA
59.79
EV/Sales
12.08
The EPS has soared by 55% YoY and by 22% QoQ
The stock's price to earnings (P/E) is 27% less than its last 4 quarters average of 136.9
DXCM's P/B is 18% below its 5-year quarterly average of 21.0 and 16% below its last 4 quarters average of 20.4
The company's equity fell by 7% YoY and by 6% QoQ
The stock's price to sales (P/S) is 28% less than its 5-year quarterly average of 15.7 and 21% less than its last 4 quarters average of 14.2
Dexcom's revenue has increased by 20% YoY and by 6% from the previous quarter

Efficiency

How efficient is Dexcom business performance
DXCM's return on invested capital has surged by 85% year-on-year and by 16% since the previous quarter
The ROE has soared by 62% year-on-year and by 24% since the previous quarter
The ROS has soared by 62% YoY and by 15% QoQ
Dexcom's ROA has increased by 37% YoY and by 13% from the previous quarter

Dividends

What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DXCM.

Financial health

How did Dexcom financials performed over time
The company's total assets is 44% higher than its total liabilities
The total liabilities has surged by 59% year-on-year and by 44% since the previous quarter
Dexcom's current ratio has decreased by 49% YoY but it has increased by 20% QoQ
The debt is 58% more than the equity
DXCM's debt to equity has soared by 72% YoY and by 70% QoQ
The debt has soared by 60% YoY and by 59% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.